PatientsVille.com Logo

Dermatitis and Doxycycline

PatientsVille

Dermatitis Symptoms and Causes

A rash is an area of irritated or swollen skin. Many rashes are itchy, red, painful, and irritated. Some rashes can also lead to blisters or patches of raw skin. Rashes are a symptom of many different medical problems. Other causes include irritating substances and allergies. Certain genes can make people more likely to get rashes.

Contact Dermatitis is a common type of rash. It causes redness, itching, and sometimes small bumps. You get the rash where you have touched an irritant, such as a chemical, or something you are allergic to, like poison ivy.

Some rashes develop right away. Others form over several days. Although most rashes clear up fairly quickly, others are long-lasting and need long-term treatment.

Because rashes can be caused by many different things, it's important to figure out what kind you have before you treat it. If it is a bad rash, if it does not go away, or if you have other symptoms, you should see your health care provider. Treatments may include moisturizers, lotions, baths, cortisone creams that relieve swelling, and antihistamines, which relieve itching.

Check out the latest treatments for dermatitis

dermatitis treatment research studies

Doxycycline clinical trials, surveys and public health registries


Find Drug Side Effect reports



Doxycycline Side Effects

Headache (186)
Nausea (176)
Rash (131)
Pain (126)
Dizziness (126)
Vomiting (125)
Dyspnoea (125)
Haemorrhage (116)
Malaise (114)
Diarrhoea (111)
Oesophageal Ulcer (100)
Pyrexia (97)
Fatigue (95)
Chest Pain (95)
Anxiety (94)
Pruritus (92)
Abortion Incomplete (91)
Photosensitivity Reaction (88)
Asthenia (82)
Abdominal Pain Upper (71)
Depression (41)
Abdominal Pain (40)
Anaemia (38)
Stevens-johnson Syndrome (35)
Suicidal Ideation (34)
Muscle Spasms (32)
Confusional State (32)
Vision Blurred (31)
Oesophagitis (31)
Oedema Peripheral (31)
Dyspepsia (30)
Hypotension (30)
Pancreatitis (30)
Syncope (30)
Benign Intracranial Hypertension (29)
Paraesthesia (28)
Palpitations (28)
Arthralgia (27)
Erythema (27)
Visual Impairment (27)
Intracranial Pressure Increased (27)
Pulmonary Embolism (27)
Dysphagia (26)
Blister (26)
Abdominal Discomfort (25)
Pancreatitis Acute (25)
Renal Failure Acute (25)
Panic Attack (25)
Hypersensitivity (24)
Swollen Tongue (24)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I am 11 days into a 20 day regime of Doxycycline for Staph. I am 51 and have not had a period in 2 years. 2 days ago I had some breast tenderness and this morning I woke to classic menstrual bleeding with abdominal cramps. Could the Doxycyclin

I am a 45 year old women who developed acne 4 years agao after my hysterectomy.Ihave been using doxycycline for the last 10 months......the only side effects I have experienced are nausea if pill tkn in empty stomach and weight gain ( which

I am anaemic and i've been treating my acne with doxycycline but instead my anaemia got worse i'm drowzy,my head feels heavy and i have a headache from hell.

I had these 100mg tablets for a sinus infection its gone now i take the last 1 tomorrow but after the few few days on them i ad to take 8 2 to start with then 1 a day. so after a few days on them i got 2 complaints my anus was a bit sore and neck an

I have just taken myself off Doxycycline. I had so much pressure in my skull - unable to stand for very long, felt really weak and thought I was going to pass out..A Few pains in my kidney area.

I took doxycycline for 10 days for perioral dermatitis. A week after completing the medicine I went to the ER with a burning in my chest. Then I lost my appetite, was nauseousand started losing weight. Three weeks later I was diagnosed with

I was taking doxycycline for an MRSA staph infection. I had tightness in my chest and worsening difficulty breathing, sore tongue, burning palms and soles of my feet, and extreme exhaustion. At the end of my 9th day on the medication, I had excruti

I was taking doxycycline for meibomitis and a little over 2 weeks after I started I came ill with severe head pressure,tinnitus,chills,nausea,flulike symptoms and after 2 emergency room visits and 6 different doctors (who were trying to treat me for

I was taking them as an anti-malarial. Caused a duodenal ulcer and a bleed on the brain, either of which could have killed me. Both nearly did, I had 3 months in hospital and 8 operations before I was discharged. I will probably never be properly wel

I'm currently taking doxycycline for Lyme disease, and about a week into my month prescription, I started having severe itching all over my body. It keeps me up at night, and when I asked if there was anything else I could switch to, I was told that

Diagnosed with spongiotic dermatitis. wicked breakout, rash, hives, unbearable itch.

Hi...I have used atopiclair on my 5year old son. is it proper? also noticed a dimple on the right side of his bom, and right on that dimple, the skin is a little lighter than his skin. He has this contact dermatitis but i have stopped the use of t

I have had Dermatitis Herpetiformis now for over 20 years and I have been on dapsone since then and have not really noticed much change except that I don't itch quit so bad as long as it doesn't take a turn to break out real bad.

I have just finished a 28 day course of Xeloda with radiation therapy for high rectal tumor. 5 days on, two days off. Cruised thru with no problems. However, I have now developed a sudden and severe ulcerative dermatitis of my glans penis. Any though

I took doxycycline for 10 days for perioral dermatitis. A week after completing the medicine I went to the ER with a burning in my chest. Then I lost my appetite, was nauseousand started losing weight. Three weeks later I was diagnosed with

I used tegaderm on my chest and ended up with dermatitis. The tape actually caused my skin to break down leaving a dime sized wound that is still not healed after two weeks.

I was diagnosed with dermatitis herpetiformis a year ago and prescribed Dapsone. I am afraid to take it regularly because of potential side effects and take it when I have a very irriating outbreak, which is happening more often now. Is is necessar

Dermatitis Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Photocil (Topical) for the Treatment of Atopic Dermatitis
Condition: Atopic Dermatitis
Interventions: Drug: Photocil for Atopic Dermatitis;   Other: Placebo - Sunscreen (SPF 2)
Outcome Measure: Atopic Dermatitis Area Severity Index (ADASI)
2 Unknown  Vulvar Contact Dermatitis Resulting From Urine Incontinence
Conditions: Urinary Incontinence;   Vulvar Pruritus;   Vulvar Contact Dermatitis
Intervention: Other: Questionnaires, gynecological exam , vaginal smear, and measurement of urine leakage
Outcome Measures: Prevalence of vulvar contact Dermatitis among patients with urinary incontinence;   Risk factors for urinary incontinence induced vulvar contact Dermatitis
3 Recruiting S. Aureus Colonization in Atopic Dermatitis
Condition: Atopic Dermatitis
Intervention:
Outcome Measures: Difference in rectal and nasal S. aureus colonization rates in a population of children with atopic Dermatitis;   Rates of resistance to commonly used topical antibiotic ointments in strains of S. aureus that colonize a population of children with atopic Dermatitis
4 Recruiting Laser Therapy for the Management of Radiation Dermatitis
Condition: Radiation Dermatitis
Intervention: Device: Low-Level Laser Therapy
Outcome Measures: Radiation Dermatitis Grade;   Radiation Dermatitis Assessment;   Pain;   Quality of Life;   Impact of Radiation Dermatitis;   Satisfaction with therapy
5 Recruiting Defining the Unique Skin and Blood Biomarkers of Pediatric Atopic Dermatitis
Conditions: Atopic Dermatitis;   Eczema
Intervention:
Outcome Measures: Cellular infiltrates;   Gene expression;   Correlation of biomarkers to quality of life
6 Recruiting A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis
Condition: Dermatitis, Atopic
Interventions: Drug: Ustekinumab;   Drug: Placebo;   Other: Concomitant topical medications for atopic Dermatitis
Outcome Measures: Percent change from Baseline to Week 12 in the Eczema Area and Severity Index (EASI) score;   Percentage of participants with an Investigator's Global Assessment (IGA) score of "clear" or "almost clear" at Week 12;   Change from Baseline to Week 12 in Atopic Dermatitis Itch Scale (ADIS);   Change from Baseline to Week 12 in Dermatology Life Quality Index (DLQI)
7 Recruiting A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis
Condition: Atopic Dermatitis
Interventions: Drug: CT327 ointment;   Drug: placebo
Outcome Measures: • To determine whether CT327 is effective in reducing pruritus in subjects with atopic Dermatitis, using a pruritus visual analogue scale (VAS);   • To assess efficacy of CT327 on atopic Dermatitis using the Investigator Global Assessment (IGA)
8 Unknown  Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation
Condition: Allergic Contact Dermatitis
Intervention:
Outcome Measure:
9 Unknown  Efficacy of Ipomea Pes-caprae Ointment as an add-on Therapy in Patient With Jellyfish Dermatitis
Conditions: Jellyfish Dermatitis;   Jellyfish Venoms
Intervention: Drug: Ipomea pes-caprae ointment
Outcome Measure: Healing time of the Jellyfish Dermatitis lesion (days)
10 Recruiting Registry for the Atopic Dermatitis Research Network
Conditions: Atopic Dermatitis;   Eczema Herpeticum
Intervention:
Outcome Measures: Genotype and sequence data from ADEH+ and ADEH- participants.;   Genotype and sequence data from ADEH- participants with and without bacterial colonization with S. aureus.;   Single Nucleotide Polymorphism (SNP) and Copy Number Variant (CNV) genotype data for candidate genes, including but not limited to Claudin-1 (CLDN1) and Filaggrin (FLG).;   SNP genotype data for candidate genes, including but not limited to CLDN1 and FLG, validated in samples from an independent AD population.;   Targeted deep resequencing of candidate genes, including but not limited to CLDN1.;   Analysis of S. aureus isolates for antibiotic sensitivity;   Analysis of S. aureus isolates for SCC mec DNA elements.;   Analysis of S. aureus isolates for expression of virulence or other factors.;   Expression of biomarkers, including but not limited to serum biomarkers, among AD sub-phenotypes.;   Analysis of microbial composition by 16S rDNA amplicon sequencing.;   Analysis of DNA methylation profiles;   Analysis of mRNA expression profiles in whole blood samples.;   Frequency of commensal Staphylococcus species producing antimicrobial activity
11 Recruiting Clinical Importance of Filaggrin Gene Mutation for Treatment Outcome in Atopic Dermatitis
Condition: Atopic Dermatitis
Intervention:
Outcome Measures: Filaggrin mutation;   Response to treatment;   Serum IgE
12 Recruiting Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis
Condition: Atopic Dermatitis
Intervention: Drug: Fluocinonide cream
Outcome Measures: Change in Investigator's Global Assessment of atopic Dermatitis;   Change in Actigraphy Movement Count per Hour;   Change in Eczema Area and Severity Index Score;   Change in Body Surface Area of atopic Dermatitis;   Change in Visual Analog Scale for itch;   Subject Global Assessment of atopic Dermatitis;   Adherence to Fluocinonide Cream
13 Recruiting A Randomized Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacodynamics and Clinical Efficacy of ILV-094 (an IL-22 Antibody) Administered Intravenously to Subjects With Atopic Dermatitis (AD)
Condition: Atopic Dermatitis
Interventions: Drug: ILV-094;   Drug: Placebo Comparator
Outcome Measures: To assess the clinical benefit as measured by SCORAD (Scoring of AD) of intravenous (IV) administration of ILV-094 administered to subjects with atopic Dermatitis (AD).;   To assess the clinical benefit, safety and tolerability as measured by IGA (Investigator's Global Assessment of intravenous (IV) administration of ILV-094 administered to subjects with atopic Dermatitis (AD).;   Reversal of the pathological epidermal phenotype during ILV-094 therapy
14 Recruiting Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
Condition: Treatment-resistant Pruritus Associated With Atopic Dermatitis
Interventions: Drug: VLY-686;   Drug: Placebo
Outcome Measures: Efficacy of VLY-686 on reducing chronic pruritus using Verbal Rating Scale (VRS) score and item 'pruritus' of Patient Global Assessment (PGA) Likert scale;   Efficacy of VLY-686 on reducing chronic pruritus using Visual Analog Scale (VAS);   Efficacy of VLY-686 on reducing atopic Dermatitis skin lesions using SCORAD;   Evaluate time course changes in VRS scores;   Effect of VLY-686 on physiology of skin as measured by TransEpidermal Water Loss (TEWL);   Effect of VLY-686 on the subjective measure of Patient Benefit Index (PBI).;   Measurement of nerve fiber density and NK-1 receptor density in exploratory skin biopsies.;   Number of adverse events in subjects taking placebo;   Explore the contribution of genetic factors on safety outcomes (e.g. number of adverse events, changes in vital signs, changes in laboratory values).;   Evaluate time course changes in VAS scores;   Explore the contribution of genetic factors on efficacy outcomes (e.g. VRS, VAS, SCORAD);   Number of adverse events in subjects taking VLY-686;   Effect of VLY-686 on physiology of skin as measured by Skin Hydration.;   Efficacy of VLY-686 on reducing atopic Dermatitis skin lesions using Eczema Area and Severity Index (EASI);   Effect of VLY-686 on the subjective measure of Dermatology Life Quality Index (DLQI).;   Effect of VLY-686 on the Clinical Global Impression-Change (CGI-C).
15 Recruiting Systemic Therapies for Pediatric Atopic Dermatitis
Condition: Dermatitis, Atopic
Intervention:
Outcome Measures: Reduction in Investigator Global Severity Scale (IGSS);   Reduction in SCORing Atopic Dermatitis (SCORAD) Index;   Reduction in Eczema Area and Severity Index (EASI);   Time to Response;   Rate of Taper;   Length of time before recurrent flare
16 Unknown  Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation
Condition: Seborrheic Dermatitis
Intervention: Biological: Petroleum Jelly
Outcome Measures: Measuring the Effectiveness of Petroleum Jelly in Treating Nonscalp Seborrheic Dermatitis;   Patient Satisfaction ofTreatment
17 Recruiting Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis
Condition: Atopic Dermatitis
Interventions: Drug: Ustekinumab;   Other: Placebo
Outcome Measures: A 50% or greater improvement from their baseline objective SCORAD (SCORing Atopic Dermatitis) at Week 16.;   Determine whether there is a reversal of the pathological epidermal phenotype during ustekinumab therapy and what immune pathways are suppressed during treatment with the drug at week 16.;   The proportion of subjects who achieve an improvement of 50% or greater from their baseline objective SCORAD at Week 32 (If patient received placebo first).;   Measured effects on patient quality of life using the DLQI (Dermatology Life Quality Index).;   The change in SCORAD from week16 to week 32 for patients that were treated with Ustekinumab from weeks 0-16, to measure maintenance of response after discontinuation of treatment.;   Ustekinumab's effect on the pathologic epidermal hyperplasia of lesional and non-lesional AD skin.;   Ustekinumab's suppression of expression of excess p40 production in non-lesional AD skin (decreasing systemic immune activation).;   Correlation between clinical response (measured via a decrease in SCORAD) to therapy with ustekinumab and suppression of the immune pathways (Th2, Th17, and Th22).
18 Recruiting Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis
Condition: Dermatitis, Atopic
Interventions: Device: Phoenix II (BAY81-2996);   Device: Phoenix I (BAY81-2996)
Outcome Measures: Local scored atopic Dermatitis (SCORAD) as clinical assessment by means of the intensity items of the SCORAD index;   Number of subjects with abnormal vital signs;   Number of patients with adverse events as a measure of safety and tolerability;   Erythema by means of chromametry;   Transepidermal water loss (TEWL) as a measure for skin barrier function;   Skin hydration by means of corneometry;   Intensity of pruritus by means of visual analogue scale (VAS)
19 Unknown  Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients
Conditions: Parkinson Disease;   Parkinsonism;   Seborrheic Dermatitis
Intervention: Drug: Botulinum toxin
Outcome Measure: Clinical assesment of the rash Photometric test of sebum exertion
20 Recruiting A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis
Condition: Atopic Dermatitis
Interventions: Other: Soak and smear;   Other: Dry Smear
Outcome Measures: Efficacy of corticosteroid application regimen as assessed by the Eczema Area and Severity Index (EASI);   Effect of corticosteroid ointment application regimens on serum cortisol;   Frequency of atopic Dermatitis flares in the 3 months following the two-week treatment regimen;   Adverse effects associated with each corticosteroid application regimen